Pioneering the use of psychedelics to treat mental health and addiction disorders Strong portfolio of research into psychedelics complements ongoing clinical trials What Braxia Scientific does: Braxia Scientific Corp (CSE:BRAX), formerly Champignon Brands Inc (CSE:SHRM) (OTCMKTS:SHRMF) is quickly emerging as a leader in the burgeoning field of psychedelic medicine. The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. As one of the first psychedelic companies to go public, the firm’s network of ketamine clinics complements its sharp focus on research and development.